Application of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC.
Background and objective For resectable non-small cell lung cancer (NSCLC), the CheckMate-816 study demonstrated that neoadjuvant chemoimmunotherapy increased the rate of complete pathologic response (pCR) by 21.8% compared with chemotherapy alone and resulted in a significant benefit in event-free...
| Publicado en: | Chinese Journal of Lung Cancer Vol. 26; no. 11; pp. 822 - 833 |
|---|---|
| Autores principales: | , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Chinese Journal of Lung Cancer
Nov2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |